RxDoctor Payments Data

Monique Collins

Family · Porterville, CANPI 1154885853

Payments from drug & device makers

$2,611in general payments, 2019–2025

Across 116 payments — averaging $22.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$556
  • Boehringer Ingelheim$395
  • AstraZeneca$280
  • Biohaven Pharmaceuticals, Inc.$240
  • Biohaven Pharmaceutical Holding Company Ltd.$158
  • Bayer$153
  • plus $829 from 14 others

What the payments were for

  • Food & beverage$2,611100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,611 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide16$26,609
OzempicSemaglutide23$19,369
Spiriva RespimatTiotropium Bromide14$6,371
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen59$1,014
Albuterol Sulfate HfaAlbuterol Sulfate40$985
Omeprazole50$368
Gabapentin30$307
Hydroxyzine Hcl24$300
Losartan Potassium20$251
Metoprolol Succinate15$231
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$213
Levothyroxine Sodium40$200
Lisinopril43$172
Atorvastatin Calcium48$154
Tizanidine Hcl17$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$62$45,97839 claims
Boehringer IngelheimSpiriva Respimat$395$6,37114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.

Other family in Porterville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →